Brigatinib/Brigatinib (Brigatinib) domestically produced or imported

Brigatinib/BrigatinibThe original drug is currently on the market in China and has been included in medical insurance. It is an imported drug and is sold under the name of Brigatinib Tablets (ALUNBRIG). It is understood that there is currently no domestically produced brigatinib produced and put on the market, and the specific time is not clear. Brigatinib is approved for the treatment of adult patients with advanced ALK-positive non-small cell cancer (NSCLC) who have not been previously treated with an ALK inhibitor.

Brigatinib is an inhibitor of ALK and mutated EGFR. ALK was first identified as a chromosomal rearrangement in anaplastic large cell lymphoma (ALCL). Genetic studies have shown that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer and neuroblastoma, as well as ALCL. Because ALK is not normally expressed in normal adult tissues, it is a very promising molecular target for cancer therapy. Brigatinibcan inhibitROS proto1 fusion and EGFR mutation, which has a significant impact on the central nervous system.

The imported original brand drug of brigatinib, which is marketed in China and has entered the medical insurance, Specifications30mg*14 tablets*2 tablets, may cost around RMB 8,000 per box, but only patients who meet the indications can be reimbursed, making the price relatively expensive. Currently, there are relatively cheap generic brigatinib drugs on the market overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a box of 90mg*30 tablets produced by a Bangladesh pharmaceutical factory is around 2,000 yuan (the price may fluctuate due to exchange rates).